{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T11:40:41Z","timestamp":1786534841176,"version":"build-2736575974"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,12]]},"DOI":"10.7759\/cureus.114404","type":"journal-article","created":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T11:17:16Z","timestamp":1786533436000},"source":"Crossref","is-referenced-by-count":0,"title":["Diabetes, Adiposity, and Functional Phenotypes in HFpEF: A Systematic Review of Recent Treatment-Response Evidence"],"prefix":"10.7759","author":[{"given":"Mulusew","family":"Goshe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rabia","family":"Zameer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jawad","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neha","family":"Kumari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehta","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.122.320257","article-title":"Heart failure with preserved ejection fraction: heterogeneous syndrome, diverse preclinical models","volume":"130","author":"Roh J","year":"2022","unstructured":"Roh J, Hill JA, Singh A, Valero-Mu\u00f1oz M, Sam F. Heart failure with preserved ejection fraction: heterogeneous syndrome, diverse preclinical models. Circ Res. 2022, 130:1906-25. 10.1161\/CIRCRESAHA.122.320257","journal-title":"Circ Res"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-025-03022-x","article-title":"Interplay between frailty and cardiometabolic disorders: from pathophysiology to clinical implications","volume":"25","author":"Santulli G","year":"2025","unstructured":"Santulli G, Sabatelli G, Wang B, et al.. Interplay between frailty and cardiometabolic disorders: from pathophysiology to clinical implications. Cardiovasc Diabetol. 2025, 25:1. 10.1186\/s12933-025-03022-x","journal-title":"Cardiovasc Diabetol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s10741-026-10629-z","article-title":"Reframing obesity-related HFpEF as a multiorgan syndrome: incretin-based therapies and imaging endpoints","volume":"31","author":"Mahmod M","year":"2026","unstructured":"Mahmod M, Dennis A, Lian J, Langford C, Rahimi K, Wamil M. Reframing obesity-related HFpEF as a multiorgan syndrome: incretin-based therapies and imaging endpoints. Heart Fail Rev. 2026, 31:10.1007\/s10741-026-10629-z","journal-title":"Heart Fail Rev"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3390\/diabetology7030046","article-title":"Incretin-based multi-agonist therapies for type 2 diabetes mellitus and obesity: mechanisms, clinical efficacy, and future directions","volume":"7","author":"Podder D","year":"2026","unstructured":"Podder D, Stala O, Miah A, et al.. Incretin-based multi-agonist therapies for type 2 diabetes mellitus and obesity: mechanisms, clinical efficacy, and future directions. Diabetology. 2026, 7:46. 10.3390\/diabetology7030046","journal-title":"Diabetology"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1186\/s40842-025-00248-2","article-title":"Effectiveness of SGLT2 inhibitors, incretin-based therapies, and finerenone on cardiorenal outcomes: a meta-analysis and network meta-analysis","volume":"11","author":"Shokravi A","year":"2025","unstructured":"Shokravi A, Seth J, Lu N, Mancini GB. Effectiveness of SGLT2 inhibitors, incretin-based therapies, and finerenone on cardiorenal outcomes: a meta-analysis and network meta-analysis. Cardiovasc Diabetol Endocrinol Rep. 2025, 11:37. 10.1186\/s40842-025-00248-2","journal-title":"Cardiovasc Diabetol Endocrinol Rep"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3390\/ijms27020879","article-title":"Biomarkers of cardiac metabolic flexibility in health, HFrEF and HFpEF","volume":"27","author":"Yun HR","year":"2026","unstructured":"Yun HR, Singh MK, Han S, Ranbhise JS, Ha J, Kim SS, Kang I. Biomarkers of cardiac metabolic flexibility in health, HFrEF and HFpEF. Int J Mol Sci. 2026, 27:10.3390\/ijms27020879","journal-title":"Int J Mol Sci"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1177\/1524839919893361","article-title":"A review of the PubMed PICO tool: using evidence-based practice in health education","volume":"21","author":"Brown D","year":"2020","unstructured":"Brown D. A review of the PubMed PICO tool: using evidence-based practice in health education. Health Promot Pract. 2020, 21:496-8. 10.1177\/1524839919893361","journal-title":"Health Promot Pract"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1002\/hsr2.2165","article-title":"The Cochrane risk of bias assessment tool 2 (RoB 2) versus the original RoB: a perspective on the pros and cons","volume":"7","author":"Nejadghaderi SA","year":"2024","unstructured":"Nejadghaderi SA, Balibegloo M, Rezaei N. The Cochrane risk of bias assessment tool 2 (RoB 2) versus the original RoB: a perspective on the pros and cons. Health Sci Rep. 2024, 7:e2165. 10.1002\/hsr2.2165","journal-title":"Health Sci Rep"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2025.04.059","article-title":"Impact of body mass index, central adiposity, and weight loss on the benefits of tirzepatide in HFpEF: the SUMMIT trial","volume":"86","author":"Borlaug BA","year":"2025","unstructured":"Borlaug BA, Zile MR, Kramer CM, et al.. Impact of body mass index, central adiposity, and weight loss on the benefits of tirzepatide in HFpEF: the SUMMIT trial. J Am Coll Cardiol. 2025, 86:242-55. 10.1016\/j.jacc.2025.04.059","journal-title":"J Am Coll Cardiol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2025.06.058","article-title":"Influence of type 2 diabetes on the effects of tirzepatide in patients with heart failure and a preserved ejection fraction with obesity: a prespecified stratification-based analysis","volume":"86","author":"Packer M","year":"2025","unstructured":"Packer M, Zile MR, Kramer CM, et al.. Influence of type 2 diabetes on the effects of tirzepatide in patients with heart failure and a preserved ejection fraction with obesity: a prespecified stratification-based analysis. J Am Coll Cardiol. 2025, 86:696-707. 10.1016\/j.jacc.2025.06.058","journal-title":"J Am Coll Cardiol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/dom.70164","article-title":"Dapagliflozin reduces epicardial adipose tissue in patients with heart failure and type 2 diabetes","volume":"27","author":"Alghamdi M","year":"2025","unstructured":"Alghamdi M, Dihoum A, Hakami K, et al.. Dapagliflozin reduces epicardial adipose tissue in patients with heart failure and type 2 diabetes. Diabetes Obes Metab. 2025, 27:7561-9. 10.1111\/dom.70164","journal-title":"Diabetes Obes Metab"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2025.102660","article-title":"Semaglutide and exercise function in obesity-related HFpEF: insights from the STEP-HFpEF program","volume":"13","author":"Borlaug BA","year":"2025","unstructured":"Borlaug BA, Kitzman DW, Patel S, et al.. Semaglutide and exercise function in obesity-related HFpEF: insights from the STEP-HFpEF program. JACC Heart Fail. 2025, 13:102660. 10.1016\/j.jchf.2025.102660","journal-title":"JACC Heart Fail"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2025.05.033","article-title":"Sodium-glucose cotransporter 2 inhibitor with and without an aldosterone antagonist for heart failure with preserved ejection fraction: the SOGALDI-PEF trial","volume":"86","author":"Ferreira JP","year":"2025","unstructured":"Ferreira JP, Vasques-N\u00f3voa F, Saraiva F, et al.. Sodium-glucose cotransporter 2 inhibitor with and without an aldosterone antagonist for heart failure with preserved ejection fraction: the SOGALDI-PEF trial. J Am Coll Cardiol. 2025, 86:320-33. 10.1016\/j.jacc.2025.05.033","journal-title":"J Am Coll Cardiol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2025.102610","article-title":"Frailty and effects of semaglutide in obesity-related HFpEF: findings from the STEP-HFpEF program","volume":"13","author":"Pandey A","year":"2025","unstructured":"Pandey A, Kitzman DW, Chinnakondepalli KM, et al.. Frailty and effects of semaglutide in obesity-related HFpEF: findings from the STEP-HFpEF program. JACC Heart Fail. 2025, 13:102610. 10.1016\/j.jchf.2025.102610","journal-title":"JACC Heart Fail"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker SD","year":"2021","unstructured":"Anker SD, Butler J, Filippatos G, et al.. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021, 385:1451-61. 10.1056\/NEJMoa2107038","journal-title":"N Engl J Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2410027","article-title":"Tirzepatide for heart failure with preserved ejection fraction and obesity","volume":"392","author":"Packer M","year":"2025","unstructured":"Packer M, Zile MR, Kramer CM, et al.. Tirzepatide for heart failure with preserved ejection fraction and obesity. N Engl J Med. 2025, 392:427-37. 10.1056\/NEJMoa2410027","journal-title":"N Engl J Med"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.11.033","article-title":"Heart failure with preserved ejection fraction and diabetes: JACC state-of-the-art review","volume":"73","author":"McHugh K","year":"2019","unstructured":"McHugh K, DeVore AD, Wu J, et al.. Heart failure with preserved ejection fraction and diabetes: JACC state-of-the-art review. J Am Coll Cardiol. 2019, 73:602-11. 10.1016\/j.jacc.2018.11.033","journal-title":"J Am Coll Cardiol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2306963","article-title":"Semaglutide in patients with heart failure with preserved ejection fraction and obesity","volume":"389","author":"Kosiborod MN","year":"2023","unstructured":"Kosiborod MN, Abildstr\u00f8m SZ, Borlaug BA, et al.. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med. 2023, 389:1069-84. 10.1056\/NEJMoa2306963","journal-title":"N Engl J Med"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.3391","article-title":"Changes in 6-min walk test is an independent predictor of death in chronic heart failure with reduced ejection fraction","volume":"26","author":"Myhre PL","year":"2024","unstructured":"Myhre PL, Kleiven \u00d8, Berge K, Grundtvig M, Gullestad L, \u00d8rn S. Changes in 6-min walk test is an independent predictor of death in chronic heart failure with reduced ejection fraction. Eur J Heart Fail. 2024, 26:2608-15. 10.1002\/ejhf.3391","journal-title":"Eur J Heart Fail"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.3390\/medicina61111903","article-title":"SGLT2 inhibitors in the management of cardio-renal-metabolic syndrome: a new therapeutic era","volume":"61","author":"Grigoriou K","year":"2025","unstructured":"Grigoriou K, Karakasis P, Nasoufidou A, et al.. SGLT2 inhibitors in the management of cardio-renal-metabolic syndrome: a new therapeutic era. Medicina (Kaunas). 2025, 61:10.3390\/medicina61111903","journal-title":"Medicina (Kaunas)"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/517208-diabetes-adiposity-and-functional-phenotypes-in-hfpef-a-systematic-review-of-recent-treatment-response-evidence","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T11:17:17Z","timestamp":1786533437000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/517208-diabetes-adiposity-and-functional-phenotypes-in-hfpef-a-systematic-review-of-recent-treatment-response-evidence"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,12]]},"references-count":21,"URL":"https:\/\/doi.org\/10.7759\/cureus.114404","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,12]]}}}